Skip to main content
Clinical Trials/NCT06319391
NCT06319391Active, not recruitingNot Applicable

Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation

Ziqiang Li1 site in 1 country60 target enrollmentStarted: April 1, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
Fk506

Study Overview

Brief Summary

Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose according to body weight, sometimes low dose will cause graft rejection of patients, or high dose will lead to infection and liver and kidney toxicity and other adverse reactions. Moreover, the conventional drug testing can not fully reflect the efficacy of tacrolimus, and there are shortcomings of lag, experience and passivity. FK506 is metabolized primarily by cytochrome P450 member 3A5 in the liver and intestines. CYP3A5*3 is the most important factor determining the expression level of CYP3A5. This mutation can cause variable shear and produce unstable protein, so that patients carrying CYP3A5*3/*3 gene do not express CYP3A5. Acute kidney injury is a common and important complication after liver transplantation. Despite recent advances in organ preservation, surgical techniques, and immunosuppressive protocols, the incidence of AKI after orthotopic liver transplantation remains high. AKI has a significant impact on both short - and long-term prognosis of orthotopic liver transplantation recipients. Studies have shown that orthotopic liver transplantation recipients with AKI have significantly higher mortality rates in hospital, at 28 days and at 1 year after surgery than those without AKI. In this study, the relationship between donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration was investigated, and the effect of donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration on acute kidney injury after liver transplantation was investigated. To provide guidance for individual administration of gene-directed tacrolimus in patients, and provide basis for prevention and reduction of postoperative acute kidney injury in liver transplantation patients.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients undergoing orthotopic liver transplantation in our center.
  • The postoperative immunosuppression regimen was tacrolimus、methylprednisolone and balipremumab for injection in all cases,and no drugs that interacted with tacrolimus were used.
  • The postoperative follow-up time was greater than 6 months and no serious rejection occurred during the follow-up period.

Exclusion Criteria

  • Combined organ transplantation.
  • liver transplant patients on other immunosuppressive regimens.
  • Preoperative CKD or need RRT.
  • Preoperative serum creatinine (SCr) > 133 mol/L.
  • Loss of follow-ups.

Outcomes

Primary Outcomes

Fk506

Time Frame: 1-28 days postoperatively

Tacrolimus concentration

Scr

Time Frame: 1-28 days postoperatively

Reflects indicators of kidney function

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Ziqiang Li
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Ziqiang Li

professor

Qianfoshan Hospital

Study Sites (1)

Loading locations...

Similar Trials